Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04966013 · ClinicalTrials.gov registry record · NA
Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19
A NA study, sponsored by EmitBio.
- Completed
- Registry status
- NA
- Development phase
- 216
- Enrollment target
NCT04966013 is a NA study that has completed, run by EmitBio. The registered enrollment target is 216 participants.
The verdict
NCT04966013, a NA study, has completed, sponsored by EmitBio.
- COMPLETED
- Registry status
- NA
- Development phase
- 216 participants
- Enrollment target
Study Summary
This is a randomized, sham controlled, dose finding study of the EmitBio RD-X19 device in individuals with symptomatic COVID-19 in the outpatient setting.
Interventions
- DEVICE Sham
- DEVICE RD-X19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2021-06-17 |
| Est. Completion | 2022-02-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04966013
The ClinicalTrials.gov registry entry for NCT04966013 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EmitBio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT04966013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04966013 about?
NCT04966013 is a clinical study titled "Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19". This is a randomized, sham controlled, dose finding study of the EmitBio RD-X19 device in individuals with symptomatic COVID-19 in the outpatient setting.
What is the current status of trial NCT04966013?
This trial is currently completed. It is a NA study. The enrollment target is 216 participants. The study started on 2021-06-17. Estimated completion is 2022-02-23.
What interventions are being tested in trial NCT04966013?
The interventions under investigation include: Sham (DEVICE), RD-X19 (DEVICE).
Who is sponsoring clinical trial NCT04966013?
This trial is sponsored by EmitBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.